These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 10888628)

  • 21. Antibody Responses to Immunization With HCV Envelope Glycoproteins as a Baseline for B-Cell-Based Vaccine Development.
    Chen F; Nagy K; Chavez D; Willis S; McBride R; Giang E; Honda A; Bukh J; Ordoukhanian P; Zhu J; Frey S; Lanford R; Law M
    Gastroenterology; 2020 Mar; 158(4):1058-1071.e6. PubMed ID: 31809725
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A Recombinant Hepatitis C Virus Genotype 1a E1/E2 Envelope Glycoprotein Vaccine Elicits Antibodies That Differentially Neutralize Closely Related 2a Strains through Interactions of the N-Terminal Hypervariable Region 1 of E2 with Scavenger Receptor B1.
    Johnson J; Freedman H; Logan M; Wong JAJ; Hockman D; Chen C; He J; Beard MR; Eyre NS; Baumert TF; Tyrrell DL; Law JLM; Houghton M
    J Virol; 2019 Nov; 93(22):. PubMed ID: 31462563
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Native Folding of a Recombinant gpE1/gpE2 Heterodimer Vaccine Antigen from a Precursor Protein Fused with Fc IgG.
    Logan M; Law J; Wong JAJ; Hockman D; Landi A; Chen C; Crawford K; Kundu J; Baldwin L; Johnson J; Dahiya A; LaChance G; Marcotrigiano J; Law M; Foung S; Tyrrell L; Houghton M
    J Virol; 2017 Jan; 91(1):. PubMed ID: 27795422
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Probing the antigenicity of hepatitis C virus envelope glycoprotein complex by high-throughput mutagenesis.
    Gopal R; Jackson K; Tzarum N; Kong L; Ettenger A; Guest J; Pfaff JM; Barnes T; Honda A; Giang E; Davidson E; Wilson IA; Doranz BJ; Law M
    PLoS Pathog; 2017 Dec; 13(12):e1006735. PubMed ID: 29253863
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Recombinant human monoclonal antibodies against different conformational epitopes of the E2 envelope glycoprotein of hepatitis C virus that inhibit its interaction with CD81.
    Allander T; Drakenberg K; Beyene A; Rosa D; Abrignani S; Houghton M; Widell A; Grillner L; Persson MAA
    J Gen Virol; 2000 Oct; 81(Pt 10):2451-2459. PubMed ID: 10993933
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Construction and evaluation of hepatitis C virus (HCV) DNA vaccine containing E2-gAD fusion gene].
    Wen B; Deng Y; Tan WJ; Ying X; Gao JM; Ruan L
    Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2010 Feb; 24(1):53-5. PubMed ID: 20848852
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Enhancement of immune response to a hepatitis C virus E2 DNA vaccine by an immunoglobulin Fc fusion tag.
    Sun W; Li Q; Zhu D; Feng J; Zhuang Z; Sun X; Xiao G; Duan Y
    J Med Virol; 2015 Dec; 87(12):2090-7. PubMed ID: 26010499
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Antigenicity and Immunogenicity of Differentially Glycosylated Hepatitis C Virus E2 Envelope Proteins Expressed in Mammalian and Insect Cells.
    Urbanowicz RA; Wang R; Schiel JE; Keck ZY; Kerzic MC; Lau P; Rangarajan S; Garagusi KJ; Tan L; Guest JD; Ball JK; Pierce BG; Mariuzza RA; Foung SKH; Fuerst TR
    J Virol; 2019 Apr; 93(7):. PubMed ID: 30651366
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Combined adenovirus vector and hepatitis C virus envelope protein prime-boost regimen elicits T cell and neutralizing antibody immune responses.
    Chmielewska AM; Naddeo M; Capone S; Ammendola V; Hu K; Meredith L; Verhoye L; Rychlowska M; Rappuoli R; Ulmer JB; Colloca S; Nicosia A; Cortese R; Leroux-Roels G; Balfe P; Bienkowska-Szewczyk K; Meuleman P; McKeating JA; Folgori A
    J Virol; 2014 May; 88(10):5502-10. PubMed ID: 24599994
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Genetic immunization of wild-type and hepatitis C virus transgenic mice reveals a hierarchy of cellular immune response and tolerance induction against hepatitis C virus structural proteins.
    Satoi J; Murata K; Lechmann M; Manickan E; Zhang Z; Wedemeyer H; Rehermann B; Liang TJ
    J Virol; 2001 Dec; 75(24):12121-7. PubMed ID: 11711603
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Use of conventional or replicating nucleic acid-based vaccines and recombinant Semliki forest virus-derived particles for the induction of immune responses against hepatitis C virus core and E2 antigens.
    Vidalin O; Fournillier A; Renard N; Chen M; Depla E; Boucreux D; Brinster C; Baumert T; Nakano I; Fukuda Y; Liljeström P; Trépo C; Inchauspé G
    Virology; 2000 Oct; 276(2):259-70. PubMed ID: 11040118
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Construction and characterization of chimeric hepatitis C virus E2 glycoproteins: analysis of regions critical for glycoprotein aggregation and CD81 binding.
    Patel AH; Wood J; Penin F; Dubuisson J; McKeating JA
    J Gen Virol; 2000 Dec; 81(Pt 12):2873-2883. PubMed ID: 11086118
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Fine mapping of murine antibody responses to immunization with a novel soluble form of hepatitis C virus envelope glycoprotein complex.
    Ruwona TB; Giang E; Nieusma T; Law M
    J Virol; 2014 Sep; 88(18):10459-71. PubMed ID: 24965471
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Expression of noncovalent hepatitis C virus envelope E1-E2 complexes is not required for the induction of antibodies with neutralizing properties following DNA immunization.
    Fournillier A; Depla E; Karayiannis P; Vidalin O; Maertens G; Trépo C; Inchauspé G
    J Virol; 1999 Sep; 73(9):7497-504. PubMed ID: 10438839
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immunogenicity study of a Novel DNA-Based HCV vaccine candidate.
    Salem EA; Tabll A; Salem TZ; El-Abd YS; El-Shenawy R; Shawky H; Shoman S
    Egypt J Immunol; 2024 Jul; 31(3):95-112. PubMed ID: 38995715
    [TBL] [Abstract][Full Text] [Related]  

  • 36. DNA immunization with fusion genes encoding different regions of hepatitis C virus E2 fused to the gene for hepatitis B surface antigen elicits immune responses to both HCV and HBV.
    Jin J; Yang JY; Liu J; Kong YY; Wang Y; Li GD
    World J Gastroenterol; 2002 Jun; 8(3):505-10. PubMed ID: 12046080
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Human broadly neutralizing antibodies to the envelope glycoprotein complex of hepatitis C virus.
    Giang E; Dorner M; Prentoe JC; Dreux M; Evans MJ; Bukh J; Rice CM; Ploss A; Burton DR; Law M
    Proc Natl Acad Sci U S A; 2012 Apr; 109(16):6205-10. PubMed ID: 22492964
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Enhancement of cellular immune response to DNA vaccine encoding hepatitis C virus core and envelope 2 fusion antigen by murine Fms-like tyrosine kinase 3 ligand].
    Ke JS; Zhao P; Cao J; Yu JP; Qi ZT
    Sheng Wu Gong Cheng Xue Bao; 2003 Mar; 19(2):158-62. PubMed ID: 15966314
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Oral immunization with attenuated Salmonella carrying a co-expression plasmid encoding the core and E2 proteins of hepatitis C virus capable of inducing cellular immune responses and neutralizing antibodies in mice.
    Cao J; Chen Z; Ren Y; Luo Y; Cao M; Lu W; Zhao P; Qi Z
    Vaccine; 2011 May; 29(20):3714-23. PubMed ID: 21396407
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The core domain of hepatitis C virus glycoprotein E2 generates potent cross-neutralizing antibodies in guinea pigs.
    Vietheer PT; Boo I; Gu J; McCaffrey K; Edwards S; Owczarek C; Hardy MP; Fabri L; Center RJ; Poumbourios P; Drummer HE
    Hepatology; 2017 Apr; 65(4):1117-1131. PubMed ID: 27997681
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.